Genome-wide association study in chondrocalcinosis reveals ENPP1 as a candidate therapeutic target in calcium pyrophosphate deposition disease^

Riku Takei^{1,2}, Ann Rosenthal^{3,4}, Tristan Pascart⁵, Richard J. Reynolds^{1,2}, Sara K. Tedeschi⁶, Tony R. Merriman^{1,2,7,*}

1 Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, Alabama, US

2 Birmingham Department of Veterans Affairs Health Care System, Birmingham, Alabama, US

3 Medical College of Wisconsin, Milwaukee, Wisconsin, US

4 Zablocki Veterans Affairs Medical Center, Milwaukee, Wisconsin, US

5 Lille Catholic University, Saint-Philibert Hospital, Lille, France

6 Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital

and Harvard Medical School, Boston, Massachusetts, US

7 Department of Microbiology and Immunology, University of Otago, Dunedin, New Zealand

* To whom correspondence should be addressed: tony.merriman@otago.ac.nz

^ The contents of this manuscript do not represent the views of the US Department of Veteran's Affairs or the United States Government.

ABSTRACT

Objective

The genetic basis of calcium pyrophosphate deposition (CPPD) disease is largely unknown. This limits the development of therapeutic strategies. We aimed to analyze a genome-wide association study (GWAS) on a large administrative database to identify new candidate causal genes for CPPD disease.

Methods

We used publicly available GWAS summary statistics for chondrocalcinosis and for crystal arthropathy from the Veterans Affairs Million Veteran Program in people of African (AFR) and European (EUR) ancestry. Included were 3,004 (536 AFR and 2,468 EUR) cases for chondrocalcinosis and 3,766 (700 AFR and 3,066 EUR) cases for crystal arthropathy. Our primary analysis was in chondrocalcinosis with secondary analysis in crystal arthropathy. We tested for colocalization of chondrocalcinosis genetic association signals with genetic control of gene expression.

Results

There were two genome-wide significant loci for chondrocalcinosis in both AFR and EUR, both on chromosome 6 (signals within the *ENPP1* and *RNF144B* genes). Findings were supported by analysis of the crystal arthropathy cohort. Colocalization analysis of chondrocalcinosis genetic association signals with genetic control of gene expression and alternative splicing further supported *ENPP1* and *RNF144B* as candidate casual genes. At *ENPP1* the allele that increases the risk for chondrocalcinosis associated with increased *ENPP1* expression.

Conclusion

ENPP1 encodes ectonucleotide pyrophosphatase / phosphodiesterase family member 1 that produces AMP and pyrophosphate, potentially contributing to the formation of calcium pyrophosphate crystals. Selective ENPP1 inhibitors developed for infectious disease and cancer could be repurposed for the treatment of chondrocalcinosis and CPPD disease.

INTRODUCTION

The deposition of calcium pyrophosphate crystals in articular tissues characterizes calcium pyrophosphate deposition (CPPD) disease. CPPD disease is a heterogeneous crystalline arthritis that can cause acute or chronic joint symptoms and is claimed to be the most common inflammatory arthritis in people over 60 years of age¹⁻⁴. Acute calcium pyrophosphate (CPP) crystal arthritis, historically called "pseudogout," is the most widely-recognized form of CPPD disease. It results from CPP crystals activating the NLRP3 inflammasome, leading to IL-1 β secretion and causing acute inflammatory arthritis⁵. Chondrocalcinosis, a radiographic finding that is most often due to CPPD⁶⁻⁸ (much less commonly basic calcium phosphate), is a common finding in older adults and increases in prevalence with each decade beyond age 60. In Europe and North America, the prevalence of imaging evidence of CPPD is estimated to be about 10% in middle-aged adults, depending on articular location⁹, with prevalence increasing to approximately 30% in adults over 80 years of age^{10,11}. CPPD also associates with cartilage degradation and osteoarthritis, although it remains unclear whether CPPD is a cause or consequence of these conditions¹².

There are no effective treatments for the prevention and/or dissolution of CPP crystals that would be akin to the use of urate-lowering therapy in gout, a common inflammatory arthritis also cause by deposition of crystals (monosodium urate) in joints. The pathogenesis of CPPD disease remains incompletely understood, although increased inorganic pyrophosphate (PPi) is central to the formation of CPP crystals in and around cartilage. Treatments for CPPD disease focus on the alleviation of inflammation³ most often with non-steroidal antiinflammatory drugs, colchicine or prednisone; biologics inhibiting IL-1 β and IL-6 have shown promise for patients with recurrent acute or chronic inflammatory CPP crystal arthritis^{1,3}. The US-based Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN) has recognized that there is considerable unmet need in CPPD disease¹³.

Identifying genetic associations with disease by genome-wide association studies (GWAS) has revolutionized understanding of disease etiology. However, despite the prevalence and impact of CPPD on the middle-aged and elderly population, no GWAS has been done to date. There is virtually no knowledge on the genetic basis of CPPD, with genetic studies

limited to various candidate gene studies such as *ANKH*^{14,15}, mostly because CPPD disease is not directly recorded in large biobanks¹. Here we report the findings of the first GWAS for chondrocalcinosis (cartilage calcification on imaging) and for crystal arthropathy.

METHODS

Million Veteran Program cohorts

The overall US Department of Veterans Affairs Million Veteran Program (MVP) cohort is 91.2% male with mean age of 61.9 years¹⁶. There were 121,177 individuals with genetic similarity to the 1000 Genomes Project African cohort and 449,042 individuals with genetic similarity to the European cohort¹⁶. Given that this study includes only data from the MVP we define the ancestral groups used here as African American (AFR) and European American (EUR). We used publicly-available summary statistics for each of chondrocalcinosis (Phecode 274.21) and crystal arthropathy (Phecode 274.2) from a systematic analysis of 2068 traits in 635,969 people from the MVP¹⁶. The Phecodes had been extracted from Veterans Affairs electronic records¹⁶. Phecodes are aggregates of International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) and ICD-10-CM codes that have been manually reviewed and clustered to align with distinct diseases or traits¹⁷. Phecodes enable highthroughput phenotyping using electronic health record data and outperformed ICD-9-CM codes in representing clinical phenotypes associated with known genetic variants¹⁸. Numbers of cases and controls for each phenotype are in the legend of Table 1. Ethical approval was not required for this study as freely downloadable publicly available summary statistics were used.

Analysis of GWAS summary statistics

Genotyping had been done using a customized ThermoFisher Axiom MVP 1.0 platform and imputation done using a hybrid reference panel of the African Genome Resources Panel available at the Sanger Imputation Service, and 1000 Genomes¹⁶ with subsequent variant level quality control described in ref¹⁶. The GWAS had been performed using the Scalable and Accurate Implementation of Generalized (SAIGE) mixture model¹⁹ with adjustment for age, sex and the first 10 principal components of genetic variation¹⁶. There were no summary statistics for either phenotype provided in ref¹⁶ for any other population groups. We analyzed 26,879,965 SNPs with minor allele frequency (MAF) > 0.1% (in combined cases and controls) in the AFR and 13,836,906 in the EUR cohort for chondrocalcinosis and 26,879,949 SNPs in AFR and 13,836,871 in EUR for crystal arthropathy. The metadata provided in ref¹⁶ had removed variants with a minor allele count < 30 and imputation quality < 0.3. AFR and EUR summary statistics for each of chondrocalcinosis and crystal arthropathy

were also meta-analyzed by an inverse-variance weighted random effects method using GWAMA software²⁰. Locus Zoom plots were drawn using code available from ref²¹. A genetic association signal was declared when > 1 SNP at a locus was genome-wide significant ($P < 5 \times 10^{-8}$). Colocalization analysis testing for overlap between chondrocalcinosis genetic association signals and genetic control of gene expression (expression quantitative trait locus (eQTL)) and alternative splicing (splicing quantitative trait locus (sQTL)) was done using the 'coloc' R package^{22,23} (signals were deemed colocalized if the posterior probability of colocalization (PPC) was greater than 0.8). An eQTL reflects average gene expression whereas a sQTL represents the joint effect of all splicing phenotypes mapping to a gene. The colocalization analyses were done only in EUR participants owing to GTEx having released summary statistics only for EUR participants.

RESULTS

Primary GWAS: chondrocalcinosis

There were two genome-wide significant loci in each of the AFR and EUR cohorts (**Table 1**; **Supplemental Figure 1**), both on chromosome 6. Locus zoom plots of the loci are presented in **Figure 1**. Strongly supporting that these loci are not false positives, the signals in each ancestral group were at the same genomic location, identified by the closest genes *RNF144B* and *ENPP1*. At *RNF144B* there were different lead SNPs (AFR, rs9396861; EUR, rs1886248), however with very similar effect size ($OR_{AFR} = 1.49$; $OR_{EUR} = 1.44$). The locus zoom plots suggested a second genetically-independent locus at RNF144B in EUR (lead SNP rs12524807) which was confirmed by conditioning on rs1886248 (**Figure 1**). The signals at *ENPP1* were different between EUR and AFR (71.5 kb apart), however each signal was entirely within the *ENPP1* gene.

The EUR and AFR meta-analysis of chondrocalcinosis did not reveal additional loci that fit our criteria for declaring a disease-associated signal (**Supplementary Table 1**). There were two signals evident in the locus zoom plot of the meta-analyzed *ENPP1* locus that corresponded to each of the EUR and AFR signals (**Figure 2**), albeit with a different lead SNP (rs1409181) at the EUR signal ($r^2 = 0.66$ with the EUR rs6939185 lead SNP (**Figure 1**)). At *RNF144B* the lead SNP was rs1886248, the same as in EUR but not as in AFR (**Table 1, Figure 2**).

Colocalization analysis with gene expression in chondrocalcinosis

Both *RNF144B* and *ENPP1* are widely expressed (**Supplemental Figure 2**). The lead SNPs at the respective loci map within an intron of either *RNF144B* or *ENPP1*, suggesting that their effect on chondrocalcinosis could be mediated through control of gene expression. Therefore, we tested whether the EUR lead variants associate with expression (i.e. are expression quantitative trait loci (eQTL) or alternative splicing quantitative trail loci (sQTL)) in the Genotype and Tissue Expression (GTEx) project²⁴. The C (risk) allele of rs1886248 associated with increased expression of *RNF144B* in cultured fibroblasts and skeletal muscle. Furthermore, rs1886248 associated with a *RNF144B* sQTL in 31 tissues with strongest associations in thyroid and whole blood. At the *ENPP1* locus the G (risk) allele of rs6939185

associated with increased expression of *ENPP1* in brain cerebellum, brain cerebellar hemisphere and skeletal muscle. There was no sQTL for rs6939185.

We formally tested whether the chondrocalcinosis genetic association signal genetically colocalized (overlapped) with the genetic signals of association with expression level of RNF144B or ENPP1 and splicing of RNF144B. If so, this would suggest two things; one, evidence that the causal gene at the locus was ENPP1 or RNF144B and, two, evidence that control of gene expression and/or alternative splicing mediates the effect of the GWAS signal. The chondrocalcinosis genetic association signal at *ENPP1* genetically colocalized with eQTLs in brain cerebellum and cerebellar hemisphere (posterior probability of colocalization (PPC) = 0.99 and 0.89, respectively) where the G (risk) allele of rs6939185 associates with increased expression of ENPP1. However, there was no colocalization with ENPP1 in skeletal muscle (PPC = 0.00). For *RNF144B* there was no evidence of colocalization of the chondrocalcinosis genetic association signal with an eQTL in cultured fibroblasts or skeletal muscle (PPC = 0.00 and 0.37, respectively). However, in the 31 tissues in which rs1886248 associated with alternative splicing of RNF144B there was strong evidence for colocalization of the chondrocal cinosis genetic association signal with genetic control of alternative splicing of RFN144B (PPC > 0.91 for all; adipose subcutaneous, adipose visceral omentum, artery aortic, artery coronary, artery tibial, brain cortex, brain putamen basal ganglia, brain anterior cingulate cortex, brain frontal cortex, brain nucleus accumbens basal ganglia, brain hippocampus, brain substantia nigra, brain amygdala, esophagus muscle, esophagus gastroesophageal junction, esophagus mucosa, fibroblasts cultured, heart left ventricle, lung, mammary tissue, muscle skeletal, nerve tibial, ovary, pituitary, prostate, skin sunexposed, skin not sun-exposed, spleen, uterus, whole blood, thyroid). In summary, this analysis supports both ENPP1 and RNF144B as candidate causal genes for chondrocalcinosis.

We observed in GTEx association of genetic control of gene expression with other genes at *ENPP1*. Specifically, rs6939185 associated with long non-coding RNA *RP1-131F15.2* in thyroid and pituitary, and with *ARG1* in sun-exposed skin. Colocalization was observed with *RP1-131F15.2* in both the thyroid and pituitary (PPC = 0.85 and 0.80, respectively) but not with *ARG1* (PPC = 0.00). The tissue expression pattern of *RP1-131F15.2* largely mirrored that of

ENPP1 (**Supplementary Figure 2**). In summary, this analysis supports *RP1-131F15.2* as a second candidate causal gene for chondrocalcinosis at the *ENPP1* locus.

Secondary GWAS: crystal arthropathy

The same AFR *ENPP1* chondrocalcinosis lead SNP (rs11963689) was genome-wide significant in AFR crystal arthropathy. However, in EUR there was a different lead SNP (rs766592) at *ENPP1*, which was in strong linkage disequilibrium ($r^2 = 0.97$) with the EUR chondrocalcinosis lead SNP (rs6939185) (**Table 1**). At *RNF144B* in EUR the lead SNP was the same as for chondrocalcinosis (rs1886248). The locus zoom plots (not shown) were very similar to those for chondrocalcinosis. The EUR and AFR meta-analysis did not reveal additional loci that fit our criteria for declaring a disease-associated signal.

Specific investigation of ANKH and chondrocalcinosis

The minor allele (A) of a 5'UTR G>A transition 4 bp upstream of the start codon of the *ANKH* gene (rs78431233) has previously been reported as a risk allele for chondrocalcinosis in two studies among kindreds with early-onset CPPD disease^{14,15}. We specifically examined the *ANKH* locus, where there was weak evidence for a signal within the gene in each of EUR (rs2921603, $P = 3.4 \times 10^{-4}$) and AFR (rs536902008, $P = 6.0 \times 10^{-5}$) (**Supplemental Figure 3**). However, rs78431233 was only weakly associated with chondrocalcinosis in EUR (P = 0.04) although the A allele also conferred risk (OR = 1.14). We also interrogated ClinVar²⁵ for clinically relevant genetic variants implicated in chondrocalcinosis (**Supplementary Table 2**). Of the 34 variants included in the AFR-EUR meta-analysis, two variants associated with chondrocalcinosis after correction for multiple testing ($P < 0.05/34 = 1.5 \times 10^{-3}$; rs17364066 and rs3045). Both SNPs map to the 3' UTR, and rs3045 is common in AFR and EUR (MAF = 0.11 and 0.09, respectively) whereas rs17364066 is common in EUR (MAF = 0.09) but uncommon in AFR (MAF = 0.004). Both SNPs are in complete linkage disequilibrium in EUR ($r^2 = 1.0$).

DISCUSSION

To our knowledge, this is the first report of a genome-wide association analysis in chondrocalcinosis, which is a radiographic finding typically attributed to CPPD. Illustrating the power of the unbiased approach afforded by GWAS, we identified major signals in separate cohorts of European and African ancestry within the ENPP1 and RNF144B genes. The genetic evidence implicates ENPP1 as a candidate causal gene mediating the genetic effect; the lead SNPs in each ancestral group mapped within the gene, the chondrocalcinosis risk allele was associated with increased expression of ENPP1 and the genetic signal of association with chondrocalcinosis colocalized with genetic control of expression. Genetic control of expression of the long non-coding RNA RP1-131F15.2 also colocalized with the chondrocalcinosis genetic association signal with the risk allele associating with reduced expression of RP1-131F15.2. Colocalization of a genetic signal of association with each of a long non-coding RNA and a protein-coding gene is a common phenomenon at GWAS loci (e.g. in gout²⁶) and our findings may reflect mediation of regulation of gene expression of ENPP1 by control of expression of RP1-131F15.2, which maps within ENPP1. At RNF144B our findings suggest that the genetic effect on chondrocalcinosis is mediated by an influence on RNF144B transcript isoforms.

ENPP1 encodes ectonucleotide pyrophosphatase / phosphodiesterase family member 1. It is a transmembrane glycoprotein that hydrolyzes nucleoside triphosphates, primarily adenosine triphosphate (ATP), to produce AMP and PPi. Increased ENPP1 activity, induction of ANK (a regulator of ATP transport) and subsequent production of extracellular inorganic pyrophosphate by chondrocytes could contribute to the formation of calcium pyrophosphate crystals²⁷⁻²⁹. A nucleotide analog (SK4A) was reported as a potent inhibitor of ENPP1 in whole cartilage tissue and could ameliorate ATP-induced calcium pyrophosphate crystal deposition in cultured chondrocytes³⁰. Hydrolysis of 2',3' -cG/AMP by ENPP1 inhibits the innate immune system stimulator of interferon genes (STING) pathway³¹. This has led to the development of selective ENPP1 inhibitors for treatment of infectious disease and cancer^{32,33}. In light of the causal link between ENPP1 and chondrocalcinosis, these inhibitors could potentially be repurposed for the treatment, or possibly even prevention, of CPPD in individuals with increased genetic susceptibility. However, this possibility would need careful evaluation as ENPP1 is widely expressed and effective blockage might increase levels of extracellular ATP which can have significant negative effects. Deficiency of ENPP1 is also associated with sometimes severe diseases including congenital ectopic vascular calcification and osteoporosis^{34,35}.

RNF144B is a RING domain-containing E3 ubiquitin-protein ligase. It negatively regulates apoptosis³⁶, is inducible by lipopolysaccharide in primary human macrophages and promotes IL-1 β expression³⁷. SNP rs9396861 has previously been associated with finger osteoarthritis by GWAS³⁸, with the C-allele increasing risk, consistent with our observation in chondrocalcinosis. How RNF144B could contribute to the pathogenesis of chondrocalcinosis and CPPD disease is unclear.

A limitation of GWAS methodology is that common SNPs do not capture the total heritability of the disease trait of interest. Several factors may contribute to the so-called 'missing heritability', including imperfect LD³⁹ between SNP marker and causal locus and small marker effect size⁴⁰. These limitations amplify when studying a disease trait with lower heritability. This is the case for chondrocalcinosis (estimated heritability of ~15% in the AFR cohort used here, and ~9% in EUR¹⁶), because the predictive ability of the risk alleles is diminished or sporadic cases of familial disease are governed by rare highly penetrant alleles, which appears to be the case in CPPD disease and related disorders⁴¹. Nevertheless, first published GWAS of traits typically involve smaller case sample size and can reveal important loci of moderate to large effect with biological significance. For example, the top finding from the early GWAS of serum urate was *SLC2A9*⁴² which directly implicated genetic variation in uric acid transporters expressed in the kidney that function to reabsorption and excrete urate. Likewise in the current genetic study of chondrocalcinosis, two moderate effect size loci in ENPP1 and RNF144B have been implicated and suggest pathophysiology of disease. Our study highlights the utility of GWAS in deepening our understanding of genetic mechanisms governing chondrocalcinosis and CPPD disease.

There are several limitations to this study. First, crystal arthropathy may not necessarily be due to CPPD disease, and could potentially include misclassified gout. Whilst we are unable to determine the extent to which this might have occurred, as these were publicly available GWAS summary statistics, we are confident that the crystal arthropathy Phecode accurately

captures CPPD disease, given that we detected no signal at the strong effect gout loci *SLC2A9* and *ABCG2²⁶* (**Supplemental Figure 4**). Furthermore, the Phecode for calcium pyrophosphate deposition (chondrocalcinosis) used by the MVP¹⁶ has been validated in the Veterans Affairs system⁴³. Second, chondrocalcinosis may be under-ascertained in the controls if they did not have a radiograph performed and/or coded, however this would bias the results towards the null. Thirdly, an automated approach had been used for phenotyping¹⁶, which is efficient but has not been validated using medical record review for chondrocalcinosis or crystal arthropathy. Mitigating the possibility of misclassification of other conditions as chondrocalcinosis or crystal arthropathy, Phecodes are derived using ICD codes and a prior study using VA data reported that CPPD was accurately identified using a single ICD-9 code⁴³. Finally, investigation using GTEx of association of the chondrocalcinosis genetic association signal with genetic control of gene expression and alternative splicing is limited by the tissues with gene expression data available. For example there are no data for cartilage, and we were unable to analyze genetic control of gene expression in AFR in GTEx using the publicly available GTEx data.

Acknowledgements

We thank MVP participants for their service and their continued contributions to the United States through participation in this study. We thank the Million Veteran Program, Office of Research and Development, and Veterans Health Administration for supporting the work in ref¹⁶ which generated the summary statistics on which our work was based. This work was supported in part by Merit Review IO1 BX004454 from the United States Department of Veteran's Affairs (to AR) and in part by Rheumatology Research Foundation R Bridge (to SKT).

Conflict of interest statement

RT, AR, TP, RJR declare no conflict of interest. TRM declares consulting fees from Variantbio unrelated to the content of this study. SKT declares consulting fees for Novartis, Avalo Therapeutics, Merck, Kyowa Kirin, Alexion and Fresenius Kabi unrelated to the content of this study.

Figure legends

Figure 1. Locus zoom plots of genetic association signals in chondrocalcinosis. A, the *RNF144B* locus in AFR; B, the *ENPP1* locus in AFR; C, the *RNF144B* locus in EUR; D, the *ENPP1* locus in EUR; E, the *RNF144B* locus in EUR after conditioning on rs1886248. Each dot represents a distinct SNP and the extent of linkage disequilibrium with the labelled SNP is indicated by the color key.

Figure 2. Locus zoom plots of genetic association signals in chondrocalcinosis resulting from meta-analysis of the AFR and EUR GWAS summary statistics. A, the *RNF144B* locus; B, the *ENPP1* locus with the signal attributable to EUR labelled; C, the *ENPP1* locus with the signal attributable to AFR labelled. Each dot represents a distinct SNP and the extent of linkage disequilibrium with the labelled SNP is indicated by the color key.

Supplementary Figure 1. Manhattan plots. A, chondrocalcinosis in AFR; B, crystal arthropathy in AFR; C, chondrocalcinosis in EUR; D, crystal arthropathy in EUR; E, chondrocalcinosis in AFR+EUR; F, crystal arthropathy in AFR+EUR. The red line is the threshold for genome-wide significance ($P = 5 \times 10^{-8}$) and the blue line is the threshold for suggestive significance ($P = 1 \times 10^{-6}$).

Supplementary Figure 2. Bulk tissue gene expression of *RNF144B* (A), *ENPP1* (B) and *RP1-131F15.2* (C) in GTEx data.

Supplementary Figure 3. Locus zoom plots of the *ANKH* locus in AFR (left) and EUR (right). Each dot represents a distinct SNP and the extent of linkage disequilibrium with the labelled SNP is indicated by the color key.

Supplementary Figure 4. Locus zoom plots of the strongly gout-associated loci *ABCG2* (left) and *SLC2A9* (right) in EUR crystal arthropathy. Each dot represents a distinct SNP and the extent of linkage disequilibrium with the labelled SNP is indicated by the color key.

SNP	Position	Risk allele:	OR [95% CI]	Р	Closest
	Chr:Base pairs	frequency			gene
rs9396861	6:18403902	C:0.36	1.49 [1.29, 1.71]	3.4x10 ⁻⁸	RNF144B
rs11963689	6:131889538	C:0.80	1.78 [1.47, 2.15]	3.8x10 ⁻⁹	ENPP1
rs11963689	6:131889538	C:0.80	1.64 [1.40, 1.93]	2.1x10 ⁻⁹	ENPP1
rs1886248	6:18403902	C:0.59	1.43 [1.35, 1.51]	4.0x10 ⁻³³	RNF144B
rs6939185	6:131818047	G:0.60	1.32 [1.24, 1.40]	3.5x10 ⁻¹⁹	ENPP1
rs1886248	6:18399163	C:0.59	1.36 [1.28, 1.43]	2.7x10 ⁻³¹	RNF144B
rs766592	6:131810461	G:0.60	1.27 [1.20, 1.34]	1.8x10 ⁻¹⁷	ENPP1
rs1886248	6:18403902	C:0.39	1.43 [1.35, 1.50]	3.6x10 ⁻⁴⁰	RNF144B
rs1409181	6:131828160	G:0.47	1.26 [1.19, 1.33]	2.3x10 ⁻¹⁷	ENPP1
rs9396861	6:18403902	C:0.46	1.37 [1.30, 1.44]	2.5x10 ⁻³⁶	RNF144B
rs1409181	6:131828160	G:0.47	1.21 [1.27, 1.16]	3.8x10 ⁻¹⁵	ENPP1
	SNP rs9396861 rs11963689 rs11963689 rs1886248 rs6939185 rs1886248 rs766592 rs1886248 rs766592 rs1886248 rs1409181 rs9396861 rs1409181	SNP Position Chr:Base pairs rs9396861 6:18403902 rs11963689 6:131889538 rs11963689 6:131889538 rs11963689 6:131889538 rs11963689 6:131889538 rs1886248 6:18403902 rs6939185 6:131818047 rs1886248 6:18399163 rs766592 6:131810461	SNP Position Chr:Base pairs Risk allele: frequency rs9396861 6:18403902 C:0.36 rs11963689 6:131889538 C:0.80 rs11963689 6:131889538 C:0.80 rs11963689 6:131889538 C:0.80 rs11866248 6:18403902 C:0.59 rs6939185 6:131818047 G:0.60 rs1886248 6:18399163 C:0.59 rs766592 6:131810461 G:0.60 rs1409181 6:131828160 G:0.47 rs9396861 6:131828160 G:0.47	SNP Position Chr:Base pairs Risk allele: frequency OR [95% Cl] rs9396861 6:18403902 C:0.36 1.49 [1.29, 1.71] rs11963689 6:131889538 C:0.80 1.78 [1.47, 2.15] rs11963689 6:131889538 C:0.80 1.64 [1.40, 1.93] rs1886248 6:18403902 C:0.59 1.43 [1.35, 1.51] rs6939185 6:131818047 G:0.60 1.32 [1.24, 1.40] rs1886248 6:18399163 C:0.59 1.36 [1.28, 1.43] rs766592 6:131810461 G:0.60 1.27 [1.20, 1.34] rs1886248 6:18403902 C:0.39 1.43 [1.35, 1.50] rs1886248 6:18403902 C:0.39 1.43 [1.35, 1.50] rs1886248 6:18403902 C:0.39 1.43 [1.35, 1.50] rs1886248 6:131828160 G:0.47 1.26 [1.19, 1.33] rs9396861 6:18403902 C:0.46 1.37 [1.30, 1.44] rs1409181 6:131828160 G:0.47 1.21 [1.27, 1.16]	SNP Position Chr:Base pairs Risk allele: frequency OR [95% Cl] P rs9396861 6:18403902 C:0.36 1.49 [1.29, 1.71] 3.4x10 ⁻⁸ rs11963689 6:131889538 C:0.80 1.78 [1.47, 2.15] 3.8x10 ⁻⁹ rs11963689 6:131889538 C:0.80 1.64 [1.40, 1.93] 2.1x10 ⁻⁹ rs1186248 6:18403902 C:0.59 1.43 [1.35, 1.51] 4.0x10 ⁻³³ rs6939185 6:131818047 G:0.60 1.32 [1.24, 1.40] 3.5x10 ⁻¹⁹ rs1886248 6:18399163 C:0.59 1.36 [1.28, 1.43] 2.7x10 ⁻³¹ rs766592 6:131810461 G:0.60 1.27 [1.20, 1.34] 1.8x10 ⁻¹⁷ rs1886248 6:18403902 C:0.39 1.43 [1.35, 1.50] 3.6x10 ⁻⁴⁰ rs1886248 6:131828160 G:0.47 1.26 [1.19, 1.33] 2.3x10 ⁻¹⁷ rs9396861 6:18403902 C:0.46 1.37 [1.30, 1.44] 2.5x10 ⁻³⁶ rs1409181 6:131828160 G:0.47 1.21 [1.27, 1.16] 3.8x10 ⁻¹⁵

Table 1

1 There were 536 AFR CC cases and 120,708 controls; 700 AFR CA cases and 120,306 controls; 2,468 EUR CC cases and 445,620 controls; 3,066 EUR CA cases and 444,490 controls. AFR, African; CC, chondrocalcinosis; CA, crystal arthropathies; EUR, European.

References

1. Pascart T, Filippou G, Lioté F, et al. Calcium pyrophosphate deposition disease. Lancet Rheumatol 2024; Online ahead of print.

2. Pascart T, Latourte A, Tedeschi SK, et al. Features associated with different inflammatory phenotypes of calcium pyrophosphate deposition (CPPD) disease: study using data from the international ACR/EULAR CPPD classification criteria cohort. Arthritis Rheumatol 2024; Online ahead of print.

3. Latourte A, Ea H-K, Richette P. Calcium pyrophosphate and basic calcium phosphate crystal arthritis: 2023 in review. Gout Urate Cryst Deposition Dis 2024;2:101-7.

4. Abhishek A, Tedeschi SK, Pascart T, et al. The 2023 ACR/EULAR classification criteria for calcium pyrophosphate deposition disease. Arthritis Rheumatol 2023;75:1703-13.

5. Martinon F, Petrilli V, Mayor A, et al. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006;440:237-41.

6. Sirotti S, Becce F, Sconfienza LM, et al. Reliability and diagnostic accuracy of radiography for the diagnosis of calcium pyrophosphate deposition: performance of the novel definitions developed by an international multidisciplinary working group. Arthritis Rheumatol 2023;75:630-8.

7. Tedeschi SK, Becce F, Pascart T, et al. Imaging features of calcium pyrophosphate deposition disease: consensus definitions from an international multidisciplinary working group. Arthritis Care Res 2023;75:825-34.

8. Tedeschi SK. A new era for calcium pyrophosphate deposition disease research: the first-ever calcium pyrophosphate deposition disease classification criteria and considerations for measuring outcomes in calcium pyrophosphate deposition disease. Gout Urate Cryst Deposition Dis 2024;2:52-9.

9. Abhishek A. Calcium pyrophosphate deposition disease: a review of epidemiologic findings. Curr Op Rheumatol 2016;28:133-9.

10. Ramonda R, Musacchio E, Perissinotto E, et al. Prevalence of chondrocalcinosis in Italian subjects from northeastern Italy. The pro. Va (PROgetto Veneto Anziani) study. Clin Exp Rheumatol 2009;27:981-4.

11. Felson D, Anderson J, Naimark A, et al. The prevalence of chondrocalcinosis in the elderly and its association with knee osteoarthritis: the Framingham Study. J Rheumatol 1989;16:1241-5.

12. Liew JW, Jarraya M, Guermazi A, et al. Intra-articular mineralization on computerized tomography of the knee and risk of cartilage damage: the Multicenter Osteoarthritis Study. Arthritis Rheumatol 2024;76:1054-61.

13. Abhishek A, Neogi T, Choi H, et al. Unmet needs and the path forward in joint disease associated with calcium pyrophosphate crystal deposition. Arthritis Rheumatol 2018;70:1182-91.

14. Abhishek A, Doherty S, Maciewicz R, et al. The association between ANKH promoter polymorphism and chondrocalcinosis is independent of age and osteoarthritis: results of a case–control study. Arthritis Res Ther 2014;16:R25.

15. Zhang Y, Johnson K, Russell RGG, et al. Association of sporadic chondrocalcinosis with a- 4-basepair G-to-A transition in the 52 -untranslated region of ANKH that promotes enhanced expression of ANKH protein and excess generation of extracellular inorganic pyrophosphate. Arthritis Rheumatol 2005;52:1110-7.

16. Verma A, Huffman JE, Rodriguez A, et al. Diversity and scale: genetic architecture of 2068 traits in the VA Million Veteran Program. Science 2024;385:eadj1182.

17. Honerlaw J, Ho Y-L, Fontin F, et al. Centralized Interactive Phenomics Resource: an integrated online phenomics knowledgebase for health data users. J Am Med Inform Assoc 2024;31:1126-34.

18. Wei W-Q, Bastarache LA, Carroll RJ, et al. Evaluating phecodes, clinical classification software, and ICD-9-CM codes for phenome-wide association studies in the electronic health record. *PLoS One*. 2017;12:e0175508.

19. Zhou W, Nielsen JB, Fritsche LG, et al. Efficiently controlling for case-control imbalance and sample relatedness in large-scale genetic association studies. Nat Genet 2018;50:1335-41.

20. Mägi R, Morris AP. GWAMA: software for genome-wide association meta-analysis. BMC Bioinformatics 2010;11:288.

21. Major TJ TR. LocusZoom-like Plots for GWAS Results (v2.1). Zenodo. 2021;https://doi.org/10.5281/zenodo.5154379

22. Boocock J, Leask M, Okada Y, et al. Genomic dissection of 43 serum urate-associated loci provides multiple insights into molecular mechanisms of urate control. Hum Mol Genet 2020;29:923-43.

23. Giambartolomei C, Vukcevic D, Schadt EE, et al. Bayesian test for colocalisation between pairs of genetic association studies using summary statistics. PLoS Genet 2014;10:e1004383.

24. Castel SE, Aguet F, Mohammadi P, et al. A vast resource of allelic expression data spanning human tissues. Genome Biol 2020;21:234.

25. Landrum MJ, Lee JM, Riley GR, et al. ClinVar: public archive of relationships among sequence variation and human phenotype. Nucl Acids Res 2014;42:D980-5.

26. Major TJ, Takei R, Matsuo H, et al. A genome-wide association analysis reveals new pathogenic pathways in gout. *Nat Genet* 2024; In press.

27. Velot É, Sébillaud S, Bianchi A. Synovial membrane is a major producer of extracellular inorganic pyrophosphate in response to hypoxia. Pharmaceuticals 2024;17:738.

28. Nasi S, Romani M, Busso N. Age-Associated Calcification: Insights from Murine Models. Gout Urate Cryst Deposition Dis 2024;2:236-51.

29. Szeri F, Niaziorimi F, Donnelly S, et al. The mineralization regulator ANKH mediates cellular efflux of ATP, not pyrophosphate. J Bone Miner Res 2020;37:1024-31.

30. Danino O, Svetitsky S, Kenigsberg S, et al. Inhibition of nucleotide pyrophosphatase/phosphodiesterase 1: implications for developing a calcium pyrophosphate deposition disease modifying drug. Rheumatol 2018;57:1472-80.

31. Li L, Yin Q, Kuss P, et al. Hydrolysis of 2☑ 3☑-cGAMP by ENPP1 and design of nonhydrolyzable analogs. Nat Chem Biol 2014;10:1043-8.

32. Kawaguchi M, Minami S, Ieda N, Nakagawa H. [1, 2, 4] Triazolo [1, 5-a] pyrimidine derivatives: Structure-activity relationship study leading to highly selective ENPP1 inhibitors. Bioorg Med Chem Lett 2024;110:129820.

33. Gao S, Hou Y, Xu Y, et al. Discovery of orally bioavailable phosphonate prodrugs of potent ENPP1 inhibitors for cancer treatment. Eur J Med Chem 2024;279:116853.

34. Ansh AJ, Stabach PR, Ciccone C, et al. Quantitative correlation of ENPP1 pathogenic variants with disease phenotype. Bone 2024;186:117136.

35. He Z, Zhu Z, Tang T, et al. Enpp1 mutations promote upregulation of hedgehog signaling in heterotopic ossification with aging. J Bone Miner Metab 2024; Online ahead of print.

36. Benard G, Neutzner A, Peng G, et al. IBRDC2, an IBR-type E3 ubiquitin ligase, is a regulatory factor for Bax and apoptosis activation. EMBO J 2010;29:1458-71.

37. Ariffin JK, Kapetanovic R, Schaale K, et al. The E3 ubiquitin ligase RNF144B is LPS-inducible in human, but not mouse, macrophages and promotes inducible IL-1 β expression. J Leuc Biol 2016;100:155-161.

38. Boer CG, Hatzikotoulas K, Southam L, et al. Deciphering osteoarthritis genetics across 826,690 individuals from 9 populations. Cell 2021;184:4784-818.

39. de Los Campos G, Vazquez AI, Fernando R, et al. Prediction of complex human traits using the genomic best linear unbiased predictor. PLoS Genet 2013;9:e1003608.

40. Manolio TA, Collins FS, Cox NJ, et al. Finding the missing heritability of complex diseases. Nature 2009;461:747-53.

41. Rodriguez-Valverde V, Zuniga M, Casanueva B, et al. Hereditary articular chondrocalcinosis: clinical and genetic features in 13 pedigrees. Am J Med 1988;84:101-6.

42. Li S, Sanna S, Maschio A, et al. The GLUT9 gene is associated with serum uric acid levels in Sardinia and Chianti cohorts. PLoS Genet 2007;3:e194.

43. Bartels CM, Singh JA, Parperis K, et al. Validation of administrative codes for calcium pyrophosphate deposition: a Veterans Administration study. J Clin Rheumatol 2015;21:189-92.





Figure 1 cont.

